nodes	percent_of_prediction	percent_of_DWPC	metapath
Propafenone—CYP1A2—Carmustine—lymphatic system cancer	0.162	0.278	CbGbCtD
Propafenone—CYP2C9—Teniposide—lymphatic system cancer	0.0981	0.168	CbGbCtD
Propafenone—ABCB1—Mitoxantrone—lymphatic system cancer	0.0666	0.114	CbGbCtD
Propafenone—CYP3A4—Cytarabine—lymphatic system cancer	0.0579	0.0994	CbGbCtD
Propafenone—CYP3A4—Teniposide—lymphatic system cancer	0.057	0.0979	CbGbCtD
Propafenone—ABCB1—Vincristine—lymphatic system cancer	0.0458	0.0787	CbGbCtD
Propafenone—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0399	0.0685	CbGbCtD
Propafenone—ABCB1—Methotrexate—lymphatic system cancer	0.0277	0.0476	CbGbCtD
Propafenone—CYP3A4—Vincristine—lymphatic system cancer	0.0275	0.0471	CbGbCtD
Propafenone—Angiopathy—Vincristine—lymphatic system cancer	0.000587	0.00141	CcSEcCtD
Propafenone—Diarrhoea—Teniposide—lymphatic system cancer	0.000586	0.0014	CcSEcCtD
Propafenone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000584	0.0014	CcSEcCtD
Propafenone—Chest pain—Bleomycin—lymphatic system cancer	0.000576	0.00138	CcSEcCtD
Propafenone—Myalgia—Bleomycin—lymphatic system cancer	0.000576	0.00138	CcSEcCtD
Propafenone—Alopecia—Vincristine—lymphatic system cancer	0.000572	0.00137	CcSEcCtD
Propafenone—Coma—Methotrexate—lymphatic system cancer	0.000572	0.00137	CcSEcCtD
Propafenone—Discomfort—Bleomycin—lymphatic system cancer	0.000569	0.00136	CcSEcCtD
Propafenone—Mental disorder—Vincristine—lymphatic system cancer	0.000567	0.00136	CcSEcCtD
Propafenone—Ecchymosis—Methotrexate—lymphatic system cancer	0.000566	0.00136	CcSEcCtD
Propafenone—Mouth ulceration—Methotrexate—lymphatic system cancer	0.000566	0.00136	CcSEcCtD
Propafenone—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000563	0.00135	CcSEcCtD
Propafenone—Alopecia—Mitoxantrone—lymphatic system cancer	0.000557	0.00134	CcSEcCtD
Propafenone—Confusional state—Bleomycin—lymphatic system cancer	0.000557	0.00133	CcSEcCtD
Propafenone—Vision blurred—Carmustine—lymphatic system cancer	0.000556	0.00133	CcSEcCtD
Propafenone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000555	0.00133	CcSEcCtD
Propafenone—Tremor—Carmustine—lymphatic system cancer	0.000553	0.00133	CcSEcCtD
Propafenone—Oedema—Bleomycin—lymphatic system cancer	0.000552	0.00132	CcSEcCtD
Propafenone—Erythema—Mitoxantrone—lymphatic system cancer	0.000549	0.00132	CcSEcCtD
Propafenone—Infection—Bleomycin—lymphatic system cancer	0.000548	0.00131	CcSEcCtD
Propafenone—Anaemia—Carmustine—lymphatic system cancer	0.000546	0.00131	CcSEcCtD
Propafenone—Vomiting—Teniposide—lymphatic system cancer	0.000545	0.00131	CcSEcCtD
Propafenone—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000541	0.0013	CcSEcCtD
Propafenone—Asthenia—Fludarabine—lymphatic system cancer	0.00054	0.00129	CcSEcCtD
Propafenone—Rash—Teniposide—lymphatic system cancer	0.00054	0.00129	CcSEcCtD
Propafenone—Dermatitis—Teniposide—lymphatic system cancer	0.00054	0.00129	CcSEcCtD
Propafenone—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000538	0.00129	CcSEcCtD
Propafenone—Headache—Teniposide—lymphatic system cancer	0.000537	0.00129	CcSEcCtD
Propafenone—Pruritus—Fludarabine—lymphatic system cancer	0.000533	0.00128	CcSEcCtD
Propafenone—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.000532	0.00128	CcSEcCtD
Propafenone—Leukopenia—Carmustine—lymphatic system cancer	0.000529	0.00127	CcSEcCtD
Propafenone—Anorexia—Bleomycin—lymphatic system cancer	0.000526	0.00126	CcSEcCtD
Propafenone—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000522	0.00125	CcSEcCtD
Propafenone—Anaemia—Vincristine—lymphatic system cancer	0.000521	0.00125	CcSEcCtD
Propafenone—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000517	0.00124	CcSEcCtD
Propafenone—Polyuria—Methotrexate—lymphatic system cancer	0.000517	0.00124	CcSEcCtD
Propafenone—Hypotension—Bleomycin—lymphatic system cancer	0.000516	0.00124	CcSEcCtD
Propafenone—Diarrhoea—Fludarabine—lymphatic system cancer	0.000515	0.00123	CcSEcCtD
Propafenone—Convulsion—Carmustine—lymphatic system cancer	0.000512	0.00123	CcSEcCtD
Propafenone—Hypertension—Carmustine—lymphatic system cancer	0.00051	0.00122	CcSEcCtD
Propafenone—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000509	0.00122	CcSEcCtD
Propafenone—Nausea—Teniposide—lymphatic system cancer	0.000509	0.00122	CcSEcCtD
Propafenone—Anaemia—Mitoxantrone—lymphatic system cancer	0.000507	0.00122	CcSEcCtD
Propafenone—Vertigo—Vincristine—lymphatic system cancer	0.000506	0.00121	CcSEcCtD
Propafenone—Leukopenia—Vincristine—lymphatic system cancer	0.000505	0.00121	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000503	0.00121	CcSEcCtD
Propafenone—Chest pain—Carmustine—lymphatic system cancer	0.000503	0.0012	CcSEcCtD
Propafenone—Myalgia—Carmustine—lymphatic system cancer	0.000503	0.0012	CcSEcCtD
Propafenone—Anxiety—Carmustine—lymphatic system cancer	0.000501	0.0012	CcSEcCtD
Propafenone—Paraesthesia—Bleomycin—lymphatic system cancer	0.000496	0.00119	CcSEcCtD
Propafenone—Malaise—Mitoxantrone—lymphatic system cancer	0.000495	0.00119	CcSEcCtD
Propafenone—Dyspnoea—Bleomycin—lymphatic system cancer	0.000492	0.00118	CcSEcCtD
Propafenone—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000491	0.00118	CcSEcCtD
Propafenone—Convulsion—Vincristine—lymphatic system cancer	0.000488	0.00117	CcSEcCtD
Propafenone—Hypertension—Vincristine—lymphatic system cancer	0.000487	0.00117	CcSEcCtD
Propafenone—Confusional state—Carmustine—lymphatic system cancer	0.000486	0.00116	CcSEcCtD
Propafenone—Oedema—Carmustine—lymphatic system cancer	0.000482	0.00115	CcSEcCtD
Propafenone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00048	0.00115	CcSEcCtD
Propafenone—Myalgia—Vincristine—lymphatic system cancer	0.00048	0.00115	CcSEcCtD
Propafenone—Cough—Mitoxantrone—lymphatic system cancer	0.000479	0.00115	CcSEcCtD
Propafenone—Infection—Carmustine—lymphatic system cancer	0.000479	0.00115	CcSEcCtD
Propafenone—Vomiting—Fludarabine—lymphatic system cancer	0.000479	0.00115	CcSEcCtD
Propafenone—Convulsion—Mitoxantrone—lymphatic system cancer	0.000476	0.00114	CcSEcCtD
Propafenone—Rash—Fludarabine—lymphatic system cancer	0.000475	0.00114	CcSEcCtD
Propafenone—Dermatitis—Fludarabine—lymphatic system cancer	0.000474	0.00114	CcSEcCtD
Propafenone—Hypertension—Mitoxantrone—lymphatic system cancer	0.000474	0.00114	CcSEcCtD
Propafenone—Pain—Bleomycin—lymphatic system cancer	0.000472	0.00113	CcSEcCtD
Propafenone—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000472	0.00113	CcSEcCtD
Propafenone—Headache—Fludarabine—lymphatic system cancer	0.000472	0.00113	CcSEcCtD
Propafenone—Tachycardia—Carmustine—lymphatic system cancer	0.00047	0.00113	CcSEcCtD
Propafenone—Chest pain—Mitoxantrone—lymphatic system cancer	0.000467	0.00112	CcSEcCtD
Propafenone—Myalgia—Mitoxantrone—lymphatic system cancer	0.000467	0.00112	CcSEcCtD
Propafenone—Anxiety—Mitoxantrone—lymphatic system cancer	0.000466	0.00112	CcSEcCtD
Propafenone—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000463	0.00111	CcSEcCtD
Propafenone—Discomfort—Mitoxantrone—lymphatic system cancer	0.000462	0.00111	CcSEcCtD
Propafenone—Oedema—Vincristine—lymphatic system cancer	0.00046	0.0011	CcSEcCtD
Propafenone—Anorexia—Carmustine—lymphatic system cancer	0.000459	0.0011	CcSEcCtD
Propafenone—Infection—Vincristine—lymphatic system cancer	0.000457	0.0011	CcSEcCtD
Propafenone—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000455	0.00109	CcSEcCtD
Propafenone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000454	0.00109	CcSEcCtD
Propafenone—Confusional state—Mitoxantrone—lymphatic system cancer	0.000452	0.00108	CcSEcCtD
Propafenone—Nervous system disorder—Vincristine—lymphatic system cancer	0.000451	0.00108	CcSEcCtD
Propafenone—Thrombocytopenia—Vincristine—lymphatic system cancer	0.00045	0.00108	CcSEcCtD
Propafenone—Hypotension—Carmustine—lymphatic system cancer	0.00045	0.00108	CcSEcCtD
Propafenone—Oedema—Mitoxantrone—lymphatic system cancer	0.000448	0.00107	CcSEcCtD
Propafenone—Nausea—Fludarabine—lymphatic system cancer	0.000447	0.00107	CcSEcCtD
Propafenone—Infection—Mitoxantrone—lymphatic system cancer	0.000445	0.00107	CcSEcCtD
Propafenone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000445	0.00107	CcSEcCtD
Propafenone—Shock—Mitoxantrone—lymphatic system cancer	0.000441	0.00106	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000439	0.00105	CcSEcCtD
Propafenone—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000439	0.00105	CcSEcCtD
Propafenone—Urticaria—Bleomycin—lymphatic system cancer	0.000439	0.00105	CcSEcCtD
Propafenone—Anorexia—Vincristine—lymphatic system cancer	0.000438	0.00105	CcSEcCtD
Propafenone—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000437	0.00105	CcSEcCtD
Propafenone—Body temperature increased—Bleomycin—lymphatic system cancer	0.000436	0.00105	CcSEcCtD
Propafenone—Insomnia—Carmustine—lymphatic system cancer	0.000436	0.00104	CcSEcCtD
Propafenone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000435	0.00104	CcSEcCtD
Propafenone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000433	0.00104	CcSEcCtD
Propafenone—Paraesthesia—Carmustine—lymphatic system cancer	0.000433	0.00104	CcSEcCtD
Propafenone—Hypotension—Vincristine—lymphatic system cancer	0.00043	0.00103	CcSEcCtD
Propafenone—Dyspnoea—Carmustine—lymphatic system cancer	0.00043	0.00103	CcSEcCtD
Propafenone—Somnolence—Carmustine—lymphatic system cancer	0.000428	0.00103	CcSEcCtD
Propafenone—Anorexia—Mitoxantrone—lymphatic system cancer	0.000427	0.00102	CcSEcCtD
Propafenone—Ataxia—Methotrexate—lymphatic system cancer	0.000427	0.00102	CcSEcCtD
Propafenone—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000419	0.001	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000419	0.001	CcSEcCtD
Propafenone—Decreased appetite—Carmustine—lymphatic system cancer	0.000419	0.001	CcSEcCtD
Propafenone—Hypotension—Mitoxantrone—lymphatic system cancer	0.000419	0.001	CcSEcCtD
Propafenone—Insomnia—Vincristine—lymphatic system cancer	0.000416	0.000997	CcSEcCtD
Propafenone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000416	0.000997	CcSEcCtD
Propafenone—Paraesthesia—Vincristine—lymphatic system cancer	0.000413	0.00099	CcSEcCtD
Propafenone—Pain—Carmustine—lymphatic system cancer	0.000412	0.000987	CcSEcCtD
Propafenone—Constipation—Carmustine—lymphatic system cancer	0.000412	0.000987	CcSEcCtD
Propafenone—Breast disorder—Methotrexate—lymphatic system cancer	0.00041	0.000983	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000408	0.000978	CcSEcCtD
Propafenone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000407	0.000975	CcSEcCtD
Propafenone—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000402	0.000964	CcSEcCtD
Propafenone—Decreased appetite—Vincristine—lymphatic system cancer	0.0004	0.000958	CcSEcCtD
Propafenone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000399	0.000957	CcSEcCtD
Propafenone—Somnolence—Mitoxantrone—lymphatic system cancer	0.000398	0.000954	CcSEcCtD
Propafenone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000397	0.000952	CcSEcCtD
Propafenone—Feeling abnormal—Carmustine—lymphatic system cancer	0.000397	0.000951	CcSEcCtD
Propafenone—Fatigue—Vincristine—lymphatic system cancer	0.000397	0.00095	CcSEcCtD
Propafenone—Asthenia—Bleomycin—lymphatic system cancer	0.000396	0.000949	CcSEcCtD
Propafenone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000394	0.000945	CcSEcCtD
Propafenone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000394	0.000944	CcSEcCtD
Propafenone—Constipation—Vincristine—lymphatic system cancer	0.000393	0.000943	CcSEcCtD
Propafenone—Pain—Vincristine—lymphatic system cancer	0.000393	0.000943	CcSEcCtD
Propafenone—Pruritus—Bleomycin—lymphatic system cancer	0.000391	0.000936	CcSEcCtD
Propafenone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000389	0.000933	CcSEcCtD
Propafenone—Eosinophilia—Methotrexate—lymphatic system cancer	0.000389	0.000931	CcSEcCtD
Propafenone—Fatigue—Mitoxantrone—lymphatic system cancer	0.000386	0.000925	CcSEcCtD
Propafenone—Pancreatitis—Methotrexate—lymphatic system cancer	0.000385	0.000922	CcSEcCtD
Propafenone—Pain—Mitoxantrone—lymphatic system cancer	0.000383	0.000918	CcSEcCtD
Propafenone—Constipation—Mitoxantrone—lymphatic system cancer	0.000383	0.000918	CcSEcCtD
Propafenone—Body temperature increased—Carmustine—lymphatic system cancer	0.000381	0.000913	CcSEcCtD
Propafenone—Abdominal pain—Carmustine—lymphatic system cancer	0.000381	0.000913	CcSEcCtD
Propafenone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000376	0.000901	CcSEcCtD
Propafenone—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000369	0.000885	CcSEcCtD
Propafenone—Dysuria—Methotrexate—lymphatic system cancer	0.000367	0.000879	CcSEcCtD
Propafenone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000366	0.000878	CcSEcCtD
Propafenone—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.000365	0.000874	CcSEcCtD
Propafenone—Abdominal pain—Vincristine—lymphatic system cancer	0.000364	0.000871	CcSEcCtD
Propafenone—Body temperature increased—Vincristine—lymphatic system cancer	0.000364	0.000871	CcSEcCtD
Propafenone—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000362	0.000866	CcSEcCtD
Propafenone—Urticaria—Mitoxantrone—lymphatic system cancer	0.000356	0.000853	CcSEcCtD
Propafenone—Hypersensitivity—Carmustine—lymphatic system cancer	0.000355	0.000851	CcSEcCtD
Propafenone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000354	0.000849	CcSEcCtD
Propafenone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000354	0.000849	CcSEcCtD
Propafenone—Vomiting—Bleomycin—lymphatic system cancer	0.000351	0.000841	CcSEcCtD
Propafenone—Infestation NOS—Methotrexate—lymphatic system cancer	0.00035	0.000839	CcSEcCtD
Propafenone—Drowsiness—Methotrexate—lymphatic system cancer	0.00035	0.000839	CcSEcCtD
Propafenone—Infestation—Methotrexate—lymphatic system cancer	0.00035	0.000839	CcSEcCtD
Propafenone—Depression—Methotrexate—lymphatic system cancer	0.000349	0.000836	CcSEcCtD
Propafenone—Rash—Bleomycin—lymphatic system cancer	0.000348	0.000834	CcSEcCtD
Propafenone—Dermatitis—Bleomycin—lymphatic system cancer	0.000348	0.000833	CcSEcCtD
Propafenone—Asthenia—Carmustine—lymphatic system cancer	0.000346	0.000828	CcSEcCtD
Propafenone—Renal failure—Methotrexate—lymphatic system cancer	0.000344	0.000824	CcSEcCtD
Propafenone—Stomatitis—Methotrexate—lymphatic system cancer	0.000341	0.000817	CcSEcCtD
Propafenone—Hypersensitivity—Vincristine—lymphatic system cancer	0.000339	0.000812	CcSEcCtD
Propafenone—Haematuria—Methotrexate—lymphatic system cancer	0.000334	0.0008	CcSEcCtD
Propafenone—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000331	0.000793	CcSEcCtD
Propafenone—Epistaxis—Methotrexate—lymphatic system cancer	0.00033	0.000791	CcSEcCtD
Propafenone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00033	0.000791	CcSEcCtD
Propafenone—Asthenia—Vincristine—lymphatic system cancer	0.00033	0.000791	CcSEcCtD
Propafenone—Diarrhoea—Carmustine—lymphatic system cancer	0.00033	0.00079	CcSEcCtD
Propafenone—Nausea—Bleomycin—lymphatic system cancer	0.000328	0.000786	CcSEcCtD
Propafenone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000327	0.000783	CcSEcCtD
Propafenone—Asthenia—Mitoxantrone—lymphatic system cancer	0.000321	0.00077	CcSEcCtD
Propafenone—Dizziness—Carmustine—lymphatic system cancer	0.000319	0.000764	CcSEcCtD
Propafenone—Haemoglobin—Methotrexate—lymphatic system cancer	0.000316	0.000757	CcSEcCtD
Propafenone—Diarrhoea—Vincristine—lymphatic system cancer	0.000315	0.000754	CcSEcCtD
Propafenone—Haemorrhage—Methotrexate—lymphatic system cancer	0.000314	0.000753	CcSEcCtD
Propafenone—Hepatitis—Methotrexate—lymphatic system cancer	0.000314	0.000753	CcSEcCtD
Propafenone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00031	0.000743	CcSEcCtD
Propafenone—Urethral disorder—Methotrexate—lymphatic system cancer	0.000308	0.000738	CcSEcCtD
Propafenone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000307	0.000734	CcSEcCtD
Propafenone—Vomiting—Carmustine—lymphatic system cancer	0.000306	0.000734	CcSEcCtD
Propafenone—Dizziness—Vincristine—lymphatic system cancer	0.000304	0.000729	CcSEcCtD
Propafenone—Rash—Carmustine—lymphatic system cancer	0.000304	0.000728	CcSEcCtD
Propafenone—Dermatitis—Carmustine—lymphatic system cancer	0.000304	0.000727	CcSEcCtD
Propafenone—Visual impairment—Methotrexate—lymphatic system cancer	0.000303	0.000725	CcSEcCtD
Propafenone—Headache—Carmustine—lymphatic system cancer	0.000302	0.000723	CcSEcCtD
Propafenone—Eye disorder—Methotrexate—lymphatic system cancer	0.000294	0.000703	CcSEcCtD
Propafenone—Tinnitus—Methotrexate—lymphatic system cancer	0.000293	0.000702	CcSEcCtD
Propafenone—Vomiting—Vincristine—lymphatic system cancer	0.000292	0.000701	CcSEcCtD
Propafenone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000292	0.000699	CcSEcCtD
Propafenone—Rash—Vincristine—lymphatic system cancer	0.00029	0.000695	CcSEcCtD
Propafenone—Dermatitis—Vincristine—lymphatic system cancer	0.00029	0.000694	CcSEcCtD
Propafenone—Headache—Vincristine—lymphatic system cancer	0.000288	0.000691	CcSEcCtD
Propafenone—Nausea—Carmustine—lymphatic system cancer	0.000286	0.000686	CcSEcCtD
Propafenone—Angiopathy—Methotrexate—lymphatic system cancer	0.000285	0.000683	CcSEcCtD
Propafenone—Vomiting—Mitoxantrone—lymphatic system cancer	0.000285	0.000683	CcSEcCtD
Propafenone—Immune system disorder—Methotrexate—lymphatic system cancer	0.000284	0.00068	CcSEcCtD
Propafenone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000283	0.000678	CcSEcCtD
Propafenone—Rash—Mitoxantrone—lymphatic system cancer	0.000282	0.000677	CcSEcCtD
Propafenone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000282	0.000676	CcSEcCtD
Propafenone—Headache—Mitoxantrone—lymphatic system cancer	0.000281	0.000672	CcSEcCtD
Propafenone—Alopecia—Methotrexate—lymphatic system cancer	0.000278	0.000665	CcSEcCtD
Propafenone—Mental disorder—Methotrexate—lymphatic system cancer	0.000275	0.00066	CcSEcCtD
Propafenone—Erythema—Methotrexate—lymphatic system cancer	0.000273	0.000655	CcSEcCtD
Propafenone—Malnutrition—Methotrexate—lymphatic system cancer	0.000273	0.000655	CcSEcCtD
Propafenone—Nausea—Vincristine—lymphatic system cancer	0.000273	0.000655	CcSEcCtD
Propafenone—Dysgeusia—Methotrexate—lymphatic system cancer	0.000268	0.000642	CcSEcCtD
Propafenone—Nausea—Mitoxantrone—lymphatic system cancer	0.000266	0.000638	CcSEcCtD
Propafenone—Vision blurred—Methotrexate—lymphatic system cancer	0.000258	0.000618	CcSEcCtD
Propafenone—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000254	0.000608	CcSEcCtD
Propafenone—Anaemia—Methotrexate—lymphatic system cancer	0.000253	0.000606	CcSEcCtD
Propafenone—Malaise—Methotrexate—lymphatic system cancer	0.000247	0.000591	CcSEcCtD
Propafenone—Vertigo—Methotrexate—lymphatic system cancer	0.000246	0.000589	CcSEcCtD
Propafenone—Leukopenia—Methotrexate—lymphatic system cancer	0.000245	0.000587	CcSEcCtD
Propafenone—Cough—Methotrexate—lymphatic system cancer	0.000239	0.000572	CcSEcCtD
Propafenone—Convulsion—Methotrexate—lymphatic system cancer	0.000237	0.000568	CcSEcCtD
Propafenone—Chest pain—Methotrexate—lymphatic system cancer	0.000233	0.000558	CcSEcCtD
Propafenone—Myalgia—Methotrexate—lymphatic system cancer	0.000233	0.000558	CcSEcCtD
Propafenone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000231	0.000554	CcSEcCtD
Propafenone—Discomfort—Methotrexate—lymphatic system cancer	0.00023	0.000551	CcSEcCtD
Propafenone—Confusional state—Methotrexate—lymphatic system cancer	0.000225	0.000539	CcSEcCtD
Propafenone—Infection—Methotrexate—lymphatic system cancer	0.000222	0.000531	CcSEcCtD
Propafenone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000219	0.000524	CcSEcCtD
Propafenone—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000219	0.000524	CcSEcCtD
Propafenone—Skin disorder—Methotrexate—lymphatic system cancer	0.000217	0.000519	CcSEcCtD
Propafenone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000216	0.000517	CcSEcCtD
Propafenone—Anorexia—Methotrexate—lymphatic system cancer	0.000213	0.00051	CcSEcCtD
Propafenone—Hypotension—Methotrexate—lymphatic system cancer	0.000209	0.0005	CcSEcCtD
Propafenone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000203	0.000487	CcSEcCtD
Propafenone—Insomnia—Methotrexate—lymphatic system cancer	0.000202	0.000484	CcSEcCtD
Propafenone—Paraesthesia—Methotrexate—lymphatic system cancer	0.0002	0.00048	CcSEcCtD
Propafenone—Dyspnoea—Methotrexate—lymphatic system cancer	0.000199	0.000477	CcSEcCtD
Propafenone—Somnolence—Methotrexate—lymphatic system cancer	0.000198	0.000475	CcSEcCtD
Propafenone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000196	0.000471	CcSEcCtD
Propafenone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000194	0.000465	CcSEcCtD
Propafenone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000193	0.000462	CcSEcCtD
Propafenone—Fatigue—Methotrexate—lymphatic system cancer	0.000192	0.000461	CcSEcCtD
Propafenone—Pain—Methotrexate—lymphatic system cancer	0.000191	0.000457	CcSEcCtD
Propafenone—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000184	0.000441	CcSEcCtD
Propafenone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000183	0.000437	CcSEcCtD
Propafenone—Urticaria—Methotrexate—lymphatic system cancer	0.000177	0.000425	CcSEcCtD
Propafenone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000176	0.000423	CcSEcCtD
Propafenone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000176	0.000423	CcSEcCtD
Propafenone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000164	0.000394	CcSEcCtD
Propafenone—Asthenia—Methotrexate—lymphatic system cancer	0.00016	0.000384	CcSEcCtD
Propafenone—Pruritus—Methotrexate—lymphatic system cancer	0.000158	0.000378	CcSEcCtD
Propafenone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000153	0.000366	CcSEcCtD
Propafenone—Dizziness—Methotrexate—lymphatic system cancer	0.000148	0.000354	CcSEcCtD
Propafenone—Vomiting—Methotrexate—lymphatic system cancer	0.000142	0.00034	CcSEcCtD
Propafenone—Rash—Methotrexate—lymphatic system cancer	0.000141	0.000337	CcSEcCtD
Propafenone—Dermatitis—Methotrexate—lymphatic system cancer	0.000141	0.000337	CcSEcCtD
Propafenone—Headache—Methotrexate—lymphatic system cancer	0.00014	0.000335	CcSEcCtD
Propafenone—Nausea—Methotrexate—lymphatic system cancer	0.000133	0.000318	CcSEcCtD
